Iovance Biotherapeutics to Host Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 1, 2019...
July 26 2019 - 7:00AM
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage
biotechnology company developing novel cancer immunotherapies based
on tumor-infiltrating lymphocyte (TIL) technology, today announced
that it will report its second quarter 2019 financial results on
Thursday, August 1, 2019. Management will host a conference call to
discuss these results and provide a corporate update at 4:30 p.m.
EDT.
To participate in the conference call, please dial
1-844-646-4465 (domestic) or 1-615-247-0257 (international) and
reference the access code 7574927. A live and archived webcast of
the call can be accessed in the Investors section of the Company’s
website at www.iovance.com or at the link:
https://edge.media-server.com/mmc/p/s6fn2wru.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics intends to commercialize autologous cell
therapy products for solid tumors and blood cancers. Tumor
infiltrating lymphocyte (TIL) therapy uses a patient’s own
cancer-fighting immune cells to attack solid tumors. TIL are
extracted from tumor cells, and once expanded through a proprietary
process are infused back into the patient. After infusion, TIL
enter tumor tissue, where they recognize, attack, and destroy the
tumor. The company is currently conducting pivotal studies in
patients with metastatic melanoma and advanced cervical cancer. In
addition, the company’s TIL therapies are being investigated for
the treatment of patients with locally advanced, recurrent or
metastatic cancers including head and neck and non-small cell lung
cancer. Iovance has also developed a T cell therapy for blood
cancers called peripheral blood lymphocyte (PBL) therapy and
intends to bring that product to the clinic to investigate
potential utility of PBL in chronic lymphocytic leukemia. For more
information, please visit www.iovance.com.
Forward-Looking Statements
Certain matters discussed in this press release are
“forward-looking statements” of Iovance Biotherapeutics, Inc.
(hereinafter referred to as the “Company,” “we,” “us,” or “our”).
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “continue,” “estimates,” “anticipates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “will,” “should” or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. The forward-looking
statements include, but are not limited to, risks and uncertainties
relating to the success, timing, projected enrollment,
manufacturing and production capabilities, and cost of our ongoing
clinical trials and anticipated clinical trials for our current
product candidates (including both Company-sponsored and
collaborator-sponsored trials in both the U.S. and Europe); the
timing of and our ability to successfully submit, obtain, and
maintain U.S. Food and Drug Administration (“FDA”) or other
regulatory authority approval of, or other action with respect to,
our product candidates; the preliminary clinical results, which may
include efficacy and safety results, presented previously from
ongoing Phase 2 studies may not be reflected in the final analyses
of these trials; enrollment and patient populations may need to be
adjusted for the Company’s trials and cohorts within those trials
based on FDA and other regulatory agency input; the successful
implementation of the Company’s research and development programs
and collaborations; the acceptance by the market of the Company’s
product candidates, if approved; and other factors, including
general economic conditions and regulatory developments, not within
the Company’s control. The factors discussed herein could cause
actual results and developments to be materially different from
those expressed in or implied by such statements. A further list
and description of the Company’s risks, uncertainties and other
factors can be found in the Company’s most recent Annual Report on
Form 10-K and the Company's subsequent filings with the Securities
and Exchange Commission. Copies of these filings are available
online at www.sec.gov or www.iovance.com. The forward-looking
statements are made only as of the date of this press release and
the Company undertakes no obligation to publicly update such
forward-looking statements to reflect subsequent events or
circumstances.
Investor Relations Contacts: Annie
ChangSolebury Trout646-378-2972achang@troutgroup.com
Chad RubinSolebury Trout646-378-2947crubin@troutgroup.com
Media Relations Contact: Rich AllanSolebury
Trout646-378-2958rallan@troutgroup.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Sep 2023 to Sep 2024